Luis Diaz
CIK 1720081 · last filed 2026-05-21
Luis Diaz is a corporate insider who has filed 12 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing, for DGX, was dated May 21, 2026. Current disclosed insider exposure totals $1.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.06M
2
12
$0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DGX | Director | 5,196 | $203.06 | $1.06M | $0 | 4 | 2026-05-21 |
| Jounce Therapeutics, Inc. (JNCE) Delisted | Director | — | $1.88 | — | $0 | 8 | 2023-05-04 |
Recent Filings
12 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-21 | DGX | Grant (A) | +1,142 | $0 | EDGAR |
| 2025-05-19 | DGX | Grant (A) | +1,203 | $0 | EDGAR |
| 2024-05-20 | DGX | Grant (A) | +1,482 | $0 | EDGAR |
| 2023-05-19 | DGX | Grant (A) | +1,369 | $0 | EDGAR |
| 2023-05-04 | Jounce Therapeutics, Inc. (JNCE) Delisted | Disp (D) | — | $0 | EDGAR |
| 2022-06-28 | Jounce Therapeutics, Inc. (JNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-22 | Jounce Therapeutics, Inc. (JNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-07-02 | Jounce Therapeutics, Inc. (JNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-29 | Jounce Therapeutics, Inc. (JNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-13 | Jounce Therapeutics, Inc. (JNCE) Delisted | Grant (A) | — | $0 | EDGAR |